Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 16/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919691 | 0.93 | PLA2G4A (0.56) | PLA2G4AS1PR1SMN1; SMN2PLA2G4B | |
| SCHEMBL3927644 | 0.85 | PLA2G4A (0.55) | PLA2G4ASMN1; SMN2PLA2G4B | |
| SCHEMBL3922467 | 0.84 | PLA2G4A (0.78) | PLA2G4A | |
| SCHEMBL3931705 | 0.83 | PLA2G4A (0.58) | PLA2G4AS1PR1SMN1; SMN2 | |
| SCHEMBL3926819 | 0.83 | PLA2G4A (0.57) | PLA2G4AS1PR1 | |
| SCHEMBL3920399 | 0.82 | PLA2G4A (0.58) | PLA2G4AS1PR1 | |
| SCHEMBL3920460 | 0.81 | PLA2G4A (0.59) | PLA2G4AS1PR1 | |
| SCHEMBL3923455 | 0.81 | S1PR1 (0.44) | PLA2G4AS1PR1SMN1; SMN2 | |
| SCHEMBL3919685 | 0.80 | PLA2G4A (0.71) | PLA2G4AS1PR1SMN1; SMN2PLA2G4B | |
| SCHEMBL3930415 | 0.80 | PLA2G4A (0.52) | PLA2G4AS1PR1SMN1; SMN2PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608633-B2 | Heteroaryl-substituted acetone derivatives as inhibitors of phospholipase A2 | MERCKLE GMBH (DE) | 2009-10-27 | — | — | US | disclosed |
| EP-1590324-B1 | NOVEL HETEROARYL-SUBSTITUTED ACETONE DERIVATIVES AS INHIBITORS OF PHOSPHOLIPASE A sb 2 /sb | MERCKLE GMBH (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | MERCKLE GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142366-A1 | Novel heteroaryl-substituted acetone derivatives as inhibitors of phospholipase a2 | PLD2, PLA2G1B, PLA2G4A | PLA2G4A 3/4885S1PR1 1120/4885SMN1; SMN2 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.